P/E at 19.83 vs Industry's 33.40: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of 19.83 for Dr Reddys Laboratories Ltd stands well below the industry average of 33.40, indicating a valuation discount of nearly 40.6%. This gap suggests that the market is pricing in either a more conservative growth outlook or perceived risks relative to peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to its growth potential and innovation pipeline, yet Dr Reddys Laboratories Ltd remains valued more modestly. This divergence raises the question of whether the discount reflects a genuine value opportunity or underlying concerns — what is the current rating?

Performance Across Timeframes: Mixed Momentum

Examining returns across multiple horizons reveals a complex performance profile. Over the past year, Dr Reddys Laboratories Ltd has delivered a 10.27% gain, outperforming the Sensex’s 3.65% loss by a wide margin. This outperformance extends to the three-year horizon, where the stock has returned 31.11% versus the Sensex’s 25.61%. However, the five-year and ten-year returns tell a different story, with the stock lagging the Sensex by a significant margin (28.58% vs 60.74% over five years and 122.16% vs 209.00% over ten years), indicating a longer-term underperformance trend.

Shorter-term momentum has been more volatile. The stock has declined 1.50% today, underperforming the sector by 2.54%, and has fallen for three consecutive days, losing 3.77% in that period. Over the past week, it is down 2.35% while the Sensex gained 0.34%. Yet, the one-month and three-month returns remain positive at 7.03% and 5.08%, respectively, both outperforming the Sensex’s 5.79% and -7.46%. This suggests a recent pullback within an otherwise resilient medium-term trend — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Signs of Short-Term Pressure

The technical setup for Dr Reddys Laboratories Ltd is revealing. The stock currently trades above its 20-day, 50-day, 100-day, and 200-day moving averages, indicating that the medium to long-term trend remains intact. However, it is below its 5-day moving average, signalling short-term weakness and recent selling pressure. This configuration often points to a temporary pullback within a broader uptrend, but the three-day consecutive decline and intraday low of Rs 1282 (-3.1%) highlight near-term volatility. The 5-day moving average acting as resistance raises the question of whether the stock will regain momentum or face further correction — is this a one-quarter anomaly or the start of a structural revenue problem?

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a positive start to the results season, with all three companies reporting so far delivering positive outcomes. This broad sector strength contrasts with the recent short-term weakness in Dr Reddys Laboratories Ltd, which has underperformed the sector by 2.54% today. The sector’s resilience may provide a supportive backdrop, but the stock’s relative underperformance in the last few days suggests company-specific factors are at play. This divergence invites further scrutiny — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Rating Reassessment: Previously Hold, Now Updated

On 23 Apr 2026, Dr Reddys Laboratories Ltd had its rating updated from Hold, reflecting a reassessment of its valuation and performance metrics. The previous Mojo Score was 71.0, indicating a solid standing within the large-cap Pharmaceuticals & Biotechnology sector. The rating update coincides with the stock’s valuation discount and mixed momentum, suggesting a recalibration of expectations. The interplay between valuation and recent price action is critical to understanding the stock’s current standing — what is the current rating?

Conclusion: Valuation Discount Meets Mixed Momentum

The data on Dr Reddys Laboratories Ltd paints a picture of a large-cap stock trading at a significant valuation discount relative to its Pharmaceuticals & Biotechnology peers. While the one-year and medium-term returns have outperformed the Sensex, the recent short-term price action shows signs of pressure, with a three-day losing streak and underperformance versus the sector. The moving average configuration supports the view of a short-term pullback within a longer-term uptrend, but the stock remains vulnerable to near-term volatility. The sector’s positive results contrast with the stock’s recent weakness, highlighting company-specific dynamics at play. Previously rated Hold, the stock’s rating was updated recently, reflecting these nuanced factors — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →